Side-by-side · Research reference
ProstamaxvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/38 cited
BFDA-ApprovedFlagship15/53 cited
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Prostamax
Semaglutide
Primary target
Chromatin in prostatic cells — pericentromeric heterochromatin regions
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Prostamax
Semaglutide
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
—
Human clinical dose
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
—
Evidence basis
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Age groups studied
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
—
Duration
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
Indefinite for chronic indication
Discontinuation results in weight regain.
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Frequency
—
Once weekly, same day each week
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
Prostamax
Semaglutide
Published adverse events
None reported in available literature
—
Genotoxicity signals
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
—
Metal ion interactions
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
—
Human safety data
Absent — no published Phase 1/2/3 trials
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Prostamax
Semaglutide
1. Route
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Reconstitution
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Frequency
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Monitoring
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Note
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Prostamax
— no documented stacks
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)